15 October 2019 Comment
Ra Pharmaceuticals focuses on assets that selectively inhibit the complement system and other immune targets, including its lead pipeline drug Zilucoplan.
11 October 2019 News
UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn.
7 October 2019 Comment
Both GPA and MPA are associated with severe symptoms and can be life-threatening disorders, so the approval of Rituxan has filled a serious unmet need.
29 August 2019 News
AstraZeneca has announced anifrolumab met the primary endpoint of the Phase III Tulip trial studying 373 systemic lupus erythematosus (SLE) patients.
14 August 2019 News
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.
1 August 2019 Comment
Baqsimi is the first emergency therapy for treating severe hypoglycemia that is administered without an injection.